Rebecca Lehto on Complementary Modalities During Lung Cancer Treatment

Sunvozertinib received FDA priority review for advanced EGFR exon 20 insertion-positive non-small cell lung cancer progressing after chemotherapy.

Nicole Gay, APRN-C, shares how nurse navigators can talk to their patients about lung cancer screening.

While the phase 2 trial did not meet its primary endpoint, it demonstrated that SBRT plus concurrent radiotherapy yielded better results than those observed in previous studies.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Durvalumab improved progression-free survival in unresectable NSCLC patients without progression post-chemoradiotherapy, reducing disease progression risk by 25% compared to placebo.

Pembrolizumab plus chemotherapy significantly improved 4-year OS and EFS in resectable early-stage NSCLC compared to chemotherapy alone.